Skip to main content

Advertisement

SpringerLink
Log in

Efficacy and safety of sofosbuvir-based regimens in chronic hepatitis C patients on dialysis

  • Original Article
  • Published:
Indian Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Introduction

Patients with end-stage renal disease (ESRD) have poor treatment tolerance and outcome to interferon-based regimens. Sofosbuvir-based regimens have improved treatment success in chronic hepatitis C. There is limited data in ESRD patients as sofosbuvir is excreted by the kidney. Several small studies have shown good results.

Methods

Sixteen consecutive patients of ESRD (on dialysis) and chronic hepatitis C were treated with sofosbuvir-based regimens as they were prospective kidney transplantation recipients, at a tertiary care center in north India. Sofosbuvir was given 400 mg on alternate days. Data is shown as number, mean (SD), and median (range).

Results

Sixteen patients (12 males) aged 45±12 years received sofosbuvir-based treatment. These patients were on hemodialysis from 10 (2–48) months. Eleven of these patients had genotype 1, four had genotype 3, and one had genotype 4 infection; baseline RNA was 7 (5–8) log. The following treatment regimens were used: sofosbuvir, ribavirin, and low dose peginterferon (n = 8; 6 genotype 1 and one each had genotype 3 and 4); sofosbuvir and daclatasvir (n = 7); sofosbuvir, ribavirin, and daclatasvir (n = 1). Ten patients achieved end of treatment response and 8 (80%) of these achieved sustained virological response at 12 weeks (SVR12); six are on treatment. Two patients with genotype one (including one with cirrhosis) had relapse. Seven patients needed blood transfusion; interferon was stopped in one due to thrombocytopenia. Fatigue was present in 4 patients.

Conclusion

Sofosbuvir-based regimens can be used in ESRD patients on dialysis with good efficacy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Morales JM, Fabrizi F. Hepatitis C and its impact on renal transplantation. Nat Rev Nephrol. 2015;11:172–82.

    Article  CAS  PubMed  Google Scholar 

  2. Duseja A, Choudhary NS, Gupta S, Dhiman RK, Chawla Y, Sakhuja V. Treatment of chronic hepatitis C in end stage renal disease: experience at a tertiary care centre. Trop Gastroenterol. 2012;33:189–92.

    Article  PubMed  Google Scholar 

  3. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932–54.

    Article  Google Scholar 

  4. Cornpropst M, Denning J, Clemons D, et al. The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of PSI-7977 [abstract 1101]. 47th Annual Meeting of the European Association for the Study of the Liver (EASL), April 18-22, 2012, Barcelona.

  5. Smolders EJ, de Kanter CT, van Hoek B, Arends JE, Drenth JP, Burger DM. Pharmacokinetics, efficacy, and safety of hepatitis C virus drugs in patients with liver and/or renal impairment. Drug Saf. 2016;39:589–611.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Saxena V, Koraishy FM, Sise ME, et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 2016;36:807–16.

    Article  CAS  PubMed  Google Scholar 

  7. Singh T, Guirguis J, Anthony S, Rivas J, Hanouneh IA, Alkhouri N. Sofosbuvir-based treatment is safe and effective in patients with chronic hepatitis C infection and end stage renal disease: a case series. Liver Int. 2016;36:802–6.

    Article  CAS  PubMed  Google Scholar 

  8. Nazario HE, Ndungu M, Modi AA. Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR <30 ml/min. Liver Int. 2016;36:798–801.

    Article  CAS  PubMed  Google Scholar 

  9. Beinhardt S, Al Zoairy R, Ferenci P, et al. DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting. Transpl Int. 2016;29:999–1007.

    Article  CAS  PubMed  Google Scholar 

  10. Desnoyer A, Pospai D, Lê MP, et al. Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol. 2016;65:40–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medanta Liver Institute, Medanta The Medicity, Gurgaon, Haryana, 122 018, India

    Narendra S Choudhary, Amit Kumar, Vijay Bodh, Sanjiv Saigal & Neeraj Saraf

  2. Medanta Kidney Institute, Medanta The Medicity, Gurgaon, Haryana, 122 018, India

    Shyam Bihari Bansal, Reetesh Sharma & Manish Jain

Authors
  1. Narendra S Choudhary
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amit Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vijay Bodh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shyam Bihari Bansal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Reetesh Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Manish Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sanjiv Saigal
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Neeraj Saraf
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Neeraj Saraf.

Ethics declarations

Conflict of interest

NSC, AK, VB, SBB, RS, MJ, SS, and NS declare that they have no conflict of interest.

Ethics statement

The authors declare that the study was performed in a manner to conform to the Helsinki declaration of 1975, as revised in 2000 and 2008 concerning Human and Animal Rights, and the authors followed the policy concerning Informed Consent as shown on Springer.com.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Choudhary, N.S., Kumar, A., Bodh, V. et al. Efficacy and safety of sofosbuvir-based regimens in chronic hepatitis C patients on dialysis. Indian J Gastroenterol 36, 113–116 (2017). https://doi.org/10.1007/s12664-017-0735-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12664-017-0735-7

Keywords

Search

Navigation